Compass Therapeutics Inc (NASDAQ: CMPX) on Monday, soared 5.83%% from the previous trading day, before settling in for the closing price of $2.4. Within the past 52 weeks, CMPX’s price has moved between $0.76 and $4.08.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -104.70% over the past five years. The company achieved an average annual earnings per share of -38.89%. With a float of $87.95 million, this company’s outstanding shares have now reached $138.28 million.
Let’s look at the performance matrix of the company that is accounted for 35 employees. In terms of profitability, gross margin is 74.8%, operating margin of -1501.0%, and the pretax margin is -1292.88%.
Compass Therapeutics Inc (CMPX) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Compass Therapeutics Inc is 36.40%, while institutional ownership is 43.20%. The most recent insider transaction that took place on May 27 ’25, was worth 21,100. In this transaction CHIEF EXECUTIVE OFFICER of this company bought 10,000 shares at a rate of $2.11, taking the stock ownership to the 6,480,825 shares. Before that another transaction happened on Apr 09 ’25, when Company’s Director sold 3,571,428 for $1.59, making the entire transaction worth $5,678,571. This insider now owns 0 shares in total.
Compass Therapeutics Inc (CMPX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -38.89% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.27% during the next five years compared to -104.70% drop over the previous five years of trading.
Compass Therapeutics Inc (NASDAQ: CMPX) Trading Performance Indicators
Compass Therapeutics Inc (CMPX) is currently performing well based on its current performance indicators. A quick ratio of 8.33 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 413.22.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.40, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.56 in one year’s time.
Technical Analysis of Compass Therapeutics Inc (CMPX)
Compass Therapeutics Inc (NASDAQ: CMPX) saw its 5-day average volume 0.82 million, a negative change from its year-to-date volume of 1.53 million. As of the previous 9 days, the stock’s Stochastic %D was 51.97%.
During the past 100 days, Compass Therapeutics Inc’s (CMPX) raw stochastic average was set at 44.00%, which indicates a significant decrease from 68.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 70.28% in the past 14 days, which was lower than the 91.82% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.06, while its 200-day Moving Average is $2.06. Nevertheless, the first resistance level for the watch stands at $2.63 in the near term. At $2.73, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.88. If the price goes on to break the first support level at $2.38, it is likely to go to the next support level at $2.23. Assuming the price breaks the second support level, the third support level stands at $2.13.
Compass Therapeutics Inc (NASDAQ: CMPX) Key Stats
Market capitalization of the company is 351.24 million based on 138,283K outstanding shares. Right now, sales total 850 K and income totals -49,380 K. The company made 0 K in profit during its latest quarter, and -16,630 K in sales during its previous quarter.
